Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks - Wikidata - awgldk - TriplyDB

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks

http://www.wikidata.org/entity/Q35554952

about

TNF-alpha inhibitors for ankylosing spondylitis Self management programme for ankylosing spondylitis Old and new treatment targets in axial spondyloarthritis Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.Update on the treatment of ankylosing spondylitis.Tumor necrosis factor-α signaling in macrophages.Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.Sleep disturbances are associated with increased pain, disease activity, depression, and anxiety in ankylosing spondylitis: a case-control study Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis.Tumor necrosis factor as a therapeutic target of rheumatologic disease.Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis.Prevalence of self-reported spondyloarthritis features in a cohort of patients with inflammatory bowel disease.Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.Biologics Use in Asian Indian Patients with Ankylosing Spondylitis: A Physician's Perspective.Treatment of ankylosing spondylitis: focus on etanercept.Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.Anti-TNF-alpha therapy with infliximab in spondyloarthritides.Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future.Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis.Etanercept: a review of its use in autoimmune inflammatory diseases.Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review.Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis.The window of opportunity: a relevant concept for axial spondyloarthritis.The relationship between inflammation and new bone formation in patients with ankylosing spondylitis.Axial spondyloarthritis: is there a treatment of choice?Patient Burden of Axial Spondyloarthritis.Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis.What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?Improving the standard of care for people with ankylosing spondylitis and a new approach to developing specialist ESP-Led AS clinics.

P2860

Q24186462-F5462860-D0A4-4D1E-A53E-D83CA2690D24 Q24187492-DBE831CF-AC24-43BD-929F-D4007165F55A Q26777906-7FA4E41B-5E42-4B1A-85D0-0C3B2F96064F Q28546596-278A2D99-106B-4E05-9097-66FA5E15F30E Q33766318-023575C4-0315-4B74-BE91-922BE4BA8F7A Q34592673-7A82A743-737F-4762-B2B6-19C2E886B0F0 Q34734335-EA32FA7D-49A6-431B-837A-1B536A2CD28E Q34896724-72C18620-9134-4293-95B9-E00DA4B276EE Q35636900-B8000C26-4794-4B50-9756-018DC7FECB8A Q35638509-A99D78B8-769A-4110-AACF-BB92E51E8198 Q35759171-083D77F3-CCD7-4634-81B8-1741FD08CF5C Q36458447-9BA540B7-41D0-4B24-AEC7-F3083753038D Q36633200-83CB891B-D144-48C8-879C-837422799EF8 Q36715135-E38707B2-C6D3-4BCC-9B04-3101AD654CA9 Q36847326-B78461B4-955A-44B2-BFBE-12BBC320F06C Q37008829-31B5C31C-F63F-4334-B1EA-7F398671EE4D Q37063563-3A306225-B90D-4DE4-BA34-5F60869225E5 Q37092635-F6857434-BE91-4505-B697-4F99268A06A7 Q37172795-75D4C1A0-C3A5-432D-8529-7F796466E9CE Q37250836-DC1748E3-355F-4D3C-AE01-73B24E91623B Q37290601-66757608-5437-4EB9-B13A-A0395C899973 Q37353748-A4964B2A-6F5B-41B5-9B82-3F7083C18BD3 Q37465416-FBDE593B-B408-4AD2-A3ED-A985620DDF24 Q37729028-D6736B8C-FAA1-4856-B9FF-827FEF5586D4 Q37882064-8A6F4C63-AED5-4BB2-96DE-5071C594E6BD Q37994661-C1F2A2BC-FBA6-4952-89D7-7F606E489FCF Q38230740-CF5BAF86-D5E5-420E-B9C0-2DA89949C03D Q38438153-ACF91CD3-E194-4227-97CE-3CF079119EFA Q38611064-2BAEDBA6-9A4E-40F4-9912-E1F0DB0E774B Q38783099-1B5D5039-2F74-4280-9F19-B7DE2DC01D49 Q38993250-92DBC699-4020-4DDE-B869-AFC318A64D02 Q38998373-7E7D8F71-2EC6-4553-A7DD-DF25AA480657 Q40791296-64F95AC0-FA15-411B-A6E7-048E343A807A Q41396084-DC380207-D32D-4925-85F3-FCBCAA8706E5 Q42013856-68AA573E-A4A1-4D45-96B8-ACAFD00C8399 Q42365374-218742B6-1721-4C46-8BC1-2C602C60CF71 Q42701796-460251DF-9D02-4724-AE4F-34AE7D0839E4 Q44934503-B50082A9-C909-4BC8-AB31-9BD747C6C8A6 Q50081141-9017CA7D-116B-483B-9157-504A7414F474 Q50929219-3391A4C7-42CA-439F-AD27-B50B2C3EDCBD

P2860

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks

http://www.wikidata.org/entity/Q35554952

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Sustained durability and toler ...... osing spondylitis for 96 weeks

@ast

Sustained durability and toler ...... osing spondylitis for 96 weeks

@en

type

label

Sustained durability and toler ...... osing spondylitis for 96 weeks

@ast

Sustained durability and toler ...... osing spondylitis for 96 weeks

@en

prefLabel

Sustained durability and toler ...... osing spondylitis for 96 weeks

@ast

Sustained durability and toler ...... osing spondylitis for 96 weeks

@en

P1433

Q35554952-AF6F9B77-4518-49FB-9852-209B6E431785

P1476

Q35554952-15E3AD79-2ED5-41AC-9922-40A503338EBF

P2093

Q35554952-0A159297-ACAB-4220-8C00-071439AD0C46

Q35554952-3A575784-D4BA-4B05-AF09-7E169C59B844

Q35554952-3B58C891-3BC1-4847-825C-15E25D176C81

Q35554952-3CE04EB3-1423-4427-9530-A44D7DA1BE33

Q35554952-5415AE67-0F88-49F9-A329-3DDA1D2485EB

Q35554952-6CEA4743-6CFB-4CD9-978B-937F086125C6

Q35554952-CB79068A-E7C7-4D41-B660-C844551AD009

Q35554952-D12C6CB9-C29B-4303-9F9D-66CEA3131D7B

Q35554952-F3929688-888A-4A33-A7CA-5EEAE204543B

Q35554952-FFE127D4-ACAF-4C2A-8D93-63A33542D3F9

P2860

Q35554952-0DC2A170-D846-4ACF-AB69-493B026A8B14

Q35554952-1A18C2C1-4186-4764-813E-1B018979ACF2

Q35554952-7C3F3163-3457-4AF9-A0F2-B5331C901C96

Q35554952-846F6175-D031-4304-AEAE-587F001E837B

Q35554952-86637539-EE5D-4A85-A335-B8D1758A2F30

Q35554952-9DA9B801-4FAD-43ED-91B6-D673FF1A22BD

Q35554952-A57F0A2B-8EC6-4023-A040-E3C633433D97

Q35554952-DEED391B-08A3-4676-B836-4708F6E73100

P304

Q35554952-5842D459-837B-49CC-A618-D3FFB99F887E

P31

Q35554952-AC61138C-4378-4E47-840F-883E81EBD2F7

P356

Q35554952-71A373CE-B208-44D7-BC26-59EBB8E662C5

P407

Q35554952-45157A96-F54C-4D44-8C22-4DF486F691DD

P433

Q35554952-7B600112-09C9-4B24-96DD-30C5D1AB02FA

P478

Q35554952-B3B9CC84-DE65-41AB-AA39-7C4265AED2DD

P50

Q35554952-DD35F955-B8A0-455E-93ED-27A29B8E1BC1

P577

Q35554952-1A0B4C2E-0971-4920-8F59-9B219E7A17F7

P5875

Q35554952-BC7D7535-0CF4-4D01-8827-CE1C96CFBA43

P698

Q35554952-987D56E4-DB8F-4790-B5C3-B1EBAD67A98C

P932

Q35554952-960A0F78-B8D4-4DC3-8A3F-74037418A22B

P356

ARD.2004.035105

P1433

Annals of the Rheumatic Diseases

P1476

Sustained durability and toler ...... osing spondylitis for 96 weeks

@en

P2093

Braun J

http://www.w3.org/2001/XMLSchema#string

Clegg D

http://www.w3.org/2001/XMLSchema#string

Cush J

http://www.w3.org/2001/XMLSchema#string

Davis JC

http://www.w3.org/2001/XMLSchema#string

Dougados M

http://www.w3.org/2001/XMLSchema#string

Kivitz A

http://www.w3.org/2001/XMLSchema#string

Solinger A

http://www.w3.org/2001/XMLSchema#string

Tsuji W

http://www.w3.org/2001/XMLSchema#string

Zhou L

http://www.w3.org/2001/XMLSchema#string

van der Heijde DM

http://www.w3.org/2001/XMLSchema#string

P2860

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis.

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

A randomized trial of etanercept as monotherapy for psoriasis.

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

P304

1557-1562

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2004.035105

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

Robert D. Inman

P577

2005-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7894967

http://www.w3.org/2001/XMLSchema#string

P698

15843448

http://www.w3.org/2001/XMLSchema#string

P932

1755272

http://www.w3.org/2001/XMLSchema#string